Aerovate Therapeutics (AVTE) Competitors $10.45 -0.69 (-6.19%) As of 07/7/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTE vs. PAHC, WVE, ELVN, VERV, NTLA, COLL, AKBA, SYRE, MLYS, and AVDLShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Phibro Animal Health (PAHC), WAVE Life Sciences (WVE), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Its Competitors Phibro Animal Health WAVE Life Sciences Enliven Therapeutics Verve Therapeutics Intellia Therapeutics Collegium Pharmaceutical Akebia Therapeutics Spyre Therapeutics Mineralys Therapeutics Avadel Pharmaceuticals Phibro Animal Health (NASDAQ:PAHC) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability. Which has higher valuation and earnings, PAHC or AVTE? Phibro Animal Health has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhibro Animal Health$1.02B1.20$2.42M$0.7838.78Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-6.15 Does the media refer more to PAHC or AVTE? In the previous week, Phibro Animal Health had 12 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 12 mentions for Phibro Animal Health and 0 mentions for Aerovate Therapeutics. Phibro Animal Health's average media sentiment score of 0.36 beat Aerovate Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Overall Sentiment Phibro Animal Health Neutral Aerovate Therapeutics Neutral Do analysts rate PAHC or AVTE? Phibro Animal Health currently has a consensus price target of $24.40, suggesting a potential downside of 19.34%. Given Phibro Animal Health's stronger consensus rating and higher possible upside, equities research analysts plainly believe Phibro Animal Health is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phibro Animal Health 2 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.83Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, PAHC or AVTE? Phibro Animal Health has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Is PAHC or AVTE more profitable? Phibro Animal Health has a net margin of 2.68% compared to Aerovate Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 30.51% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Phibro Animal Health2.68% 30.51% 6.89% Aerovate Therapeutics N/A -90.19%-77.47% Do insiders & institutionals hold more shares of PAHC or AVTE? 99.3% of Phibro Animal Health shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryPhibro Animal Health beats Aerovate Therapeutics on 14 of the 15 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$302.89M$783.33M$5.46B$8.93BDividend YieldN/A4.84%5.24%4.04%P/E Ratio-3.491.3027.0720.17Price / SalesN/A230.51381.5293.95Price / CashN/A23.4426.2128.59Price / Book2.646.138.015.59Net Income-$75.52M-$27.85M$3.17B$248.41M7 Day Performance4.60%2.46%3.53%6.17%1 Month Performance45.34%8.69%2.73%7.83%1 Year Performance-82.84%8.61%34.10%21.03% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate TherapeuticsN/A$10.45-6.2%N/A-80.2%$302.89MN/A-3.4920High Trading VolumePAHCPhibro Animal Health3.6813 of 5 stars$25.54-0.5%$21.80-14.6%+77.4%$1.04B$1.02B32.741,940Trending NewsAnalyst UpgradeWVEWAVE Life Sciences4.4251 of 5 stars$6.50-2.5%$20.50+215.4%+29.1%$1.04B$108.30M-7.74240News CoverageELVNEnliven Therapeutics2.687 of 5 stars$20.06-3.0%$39.60+97.4%-12.6%$1.01BN/A-10.4550VERVVerve Therapeutics3.4674 of 5 stars$11.23-0.6%$14.57+29.8%+112.6%$1.01B$32.33M-5.32110NTLAIntellia Therapeutics4.7052 of 5 stars$9.38-1.9%$33.37+255.7%-55.0%$990.25M$57.88M-1.79600COLLCollegium Pharmaceutical4.2589 of 5 stars$29.57-1.2%$43.75+48.0%-4.0%$961.71M$664.28M24.24210News CoverageAnalyst DowngradeBuyback AnnouncementAKBAAkebia Therapeutics4.2367 of 5 stars$3.64-0.3%$6.75+85.4%+287.9%$958.62M$160.18M-17.33430SYRESpyre Therapeutics1.3394 of 5 stars$14.97-1.6%$53.40+256.7%-40.0%$917.39M$890K-3.9773MLYSMineralys Therapeutics2.1521 of 5 stars$13.53-1.3%$32.25+138.4%+8.8%$893.55MN/A-3.6328AVDLAvadel Pharmaceuticals2.4432 of 5 stars$8.85-3.8%$18.17+105.3%-39.9%$890M$169.12M-32.7870 Related Companies and Tools Related Companies Phibro Animal Health Competitors WAVE Life Sciences Competitors Enliven Therapeutics Competitors Verve Therapeutics Competitors Intellia Therapeutics Competitors Collegium Pharmaceutical Competitors Akebia Therapeutics Competitors Spyre Therapeutics Competitors Mineralys Therapeutics Competitors Avadel Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredNobel Prize Material Finally Goes CommercialA Nobel Prize–winning material just got its biggest breakthrough in 30 years. A little-known company has cr...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTE Stock Alerts